RedShiftBio is a venture-backed innovative biotechnology startup company, developing analytical instrumentation for life science research with a primary focus on the biopharmaceutical industry. With strategic backing from two of the world’s largest life science instrumentation companies, including Waters, we have raised over $50 million in capital up to our most recent round D funding cycle, which closed in December 2019.
Our products are powered by Microfluidic Modulation Spectroscopy (MMS), a proprietary technology which addresses many of the current limitations of Infrared (IR) based spectroscopic techniques. This unique technology integrates automated sample handling with a unique microfluidic system and a quantum cascade laser based optical system to dramatically improve the resolution, repeatability, data quality, precision, and accuracy of IR spectroscopy.
Supporting our disruptive technology platform are an engineering and software development team that have developed a technology with the end-user in mind. In addition, our supporting platforms have been designed to simplify and automate as many processes as possible, from sample loading to data processing and 21 CFR – Part 11 compliance.
This combination of technologies is backed by a global support network with locations across Europe and Asia along with world class sales, applications, service, and support teams to address all market needs. Led by an experienced management team with a proven track record of success in both large instrumentation companies and commercializing disruptive technologies, RedShiftBio is here to support your research and development goals.
To deliver on the promise to bring novel analytical tools to the R&D, life science and biopharmaceutical markets unavailable through current technologies and products.
To push the boundaries of measurement solutions to bring our customers powerful new solutions in protein therapeutic development, process monitoring and quality control.